Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.
Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.